MELISSA MOODY: Open Payments
NPI 1750505384 · CHARLESTON, WV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$293,167 in 300 payments from 12 companies in 2025. Trend: 2023 $262,639 · 2024 $229,209 · 2025 $293,167
Speaker / faculty: $218,184Travel & lodging: $26,495Consulting: $24,084Honoraria: $18,425Food & beverage: $5,979
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 116 | $138,930 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 53 | $65,763 |
| Otsuka America Pharmaceutical, Inc. | 53 | $44,040 |
| ABBVIE INC. | 25 | $23,827 |
| Axsome Therapeutics, Inc. | 17 | $19,771 |
| E.R. Squibb & Sons, L.L.C. | 8 | $280 |
| Alkermes, Inc. | 13 | $263 |
| Teva Pharmaceuticals USA, Inc. | 5 | $96 |
| Lundbeck LLC | 4 | $87 |
| Vanda Pharmaceuticals Inc. | 3 | $56 |
Products named: INGREZZA, CAPLYTA, VRAYLAR, ABILIFY MAINTENA, REXULTI, Auvelity, COBENFY, ARISTADA.
Industry payments across WV — which companies pay providers there.
